Immuneering partners with Astellas on pancreatic cancer combination trials
IMRX•Immuneering will supply atebimetinib for two Astellas-sponsored trials in patients with CLDN18.2-expressing metastatic pancreatic cancer. The trials will test combinations in first-line and previously treated patients, and each company retains global rights to its respective treatments.
1. Two trials planned
Immuneering entered a collaboration with Astellas to supply atebimetinib for two Astellas-sponsored trials. One will test atebimetinib with a CLDN18.2-targeted program and modified gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer; the other will evaluate a chemotherapy-free combination in previously treated patients. Each company retains global development and commercialization rights to its respective treatments.
